Document is current

Article History

Received: 30 May 2021

Accepted: 30 September 2021

First Online: 11 October 2021

Declarations

:

: This study was granted IRB exemption for a quality improvement project by the University of Pennsylvania IRB. The University of Pennsylvania Health System facilitated access to the data for this study in accordance with this IRB exemption.

: Not applicable.

: Charu Aggarwal reports serving as an advisory board member for AZ, Bluprint, Celgene, Eli Lilly, Merck, Daichi Sankyo and research funding to institution from Merck, Macrogenics, Novartis and AZ.Abigail T. Berman reports research funding from Merck (Inst); consulting role with Astra Zeneca, Varian, legal consultancy.Lawrence N. Shulman reports research funding from the Breast Cancer Research Foundation and Bristol Myers Squibb.Joshua Bauml reports research/grant support from Merck, Clovis, Carevive Systems, Novartis, Bayer, Janssen, Astra Zeneca, Takeda, Carisma Therapeutics and consultative services for Clovis, BMS, Astra Zeneca, Celgene, Boehringer Ingleheim, Janssen, Merck, Guardant Health, Genentech, Takeda, Ayala, Regeneron, Inivata, Novartis.Corey Langer reports research funding from Eli Lilly (Inst), Trizell (Inst), AstraZeneca (Inst); Genentech/Roche (Inst) consulting role with Astra Zeneca, Novocure, Boehringer; Merck; Gilead; Pfizer, and Amgen; and previous medical writing support from Novartis.Melina E. Marmarelis reports researching funding from Eli Lilly (Inst), Trizell (Inst), AstraZeneca (Inst); consulting role with Astra Zeneca, Novocure, Boehringer Ingelheim; stock in Gilead Sciences, Portola Pharmaceuticals, Merck, Bluebird Bio, Johnson & Johnson, Pfizer; previous medical writing support from Novartis.